Armis Secures $200M in Series D, Eyes IPO with $4.2B Valuation

Armis, a leader in cyber exposure management and security, has successfully closed a $200 million Series D funding round, elevating its valuation to an impress...

S
StartupHub.ai Staff
1 min read

Armis, a leader in cyber exposure management and security, has successfully closed a $200 million Series D funding round, elevating its valuation to an impress...

Generating cover image…

Armis, a leader in cyber exposure management and security, has successfully closed a $200 million Series D funding round, elevating its valuation to an impressive $4.2 billion. Led by General Catalyst and Alkeon Capital, and joined by previous investors like Brookfield Technology Partners and Georgian, the funding will drive Armis' five-year strategic plan. This involves innovating cybersecurity products and leveraging growth opportunities globally. Known for its comprehensive security solutions through Armis Centrix™, the company has partnered with big names such as United Airlines and Colgate-Palmolive to safeguard critical IT and software assets.

Celebrating a recent jump in annual recurring revenue to over $200 million, Armis is setting its sights on an IPO, further aiming for significant revenue milestones in the near future.

With an ever-growing demand for its solutions, Armis remains focused on tackling the complex challenges within cybersecurity, maintaining an essential role for enterprises aiming to secure critical assets.

© 2024 StartupHub.ai. All rights reserved. You may not republish this article in full without a license. Search engines and AI research tools may crawl and summarize for reference. Bulk reproduction or model training requires a license. See our terms.
S

Written by

StartupHub.ai Staff

Editorial team

The staff writers of StartupHub.ai, ranging from investment analysts to avid AI tool users, early adopters and critical enthusiasts. Backgrounds span engineering, business and the arts. We hold every piece to rigorous standards of research and review.